Real, you're correct. CYCC deserves a following, so I'll jump in. Based on my risk/reward analysis, I'm a long term holder for a myriad of reasons. On a shorter term basis, the most exciting program may be the kids neuroblastoma trial, which will be run as an IST. An arm of the UK will be running the trial. COVID -19 has caused delays to the start during 2020 so even though it was recently projected to open enrollment about now, it won't be a surprise if it gets delayed for awhile longer. The pre clinical results were truly eye catching. Fadraciclib (aka CYC065) is being used as a single agent in the trial. Once the trial begins, hopefully the company will give a timeline for enrollment and completion. My guess, within 1 1/2 years, if not less.
Bullish
K
New form 13G filed by Pura Vida Investments; bought 475K shares at 6.40/share.
S
What happened?
K
I've had a small stake in this based on some of the early stage drug candidates, including (or perhaps especially) 065. When they initially reported a response with 065, was hoping this would be followed by more promising data. Esmo came and went with no promise fulfilled. But I've kept a small stake here to see what happens next. Today's events, coupled with the board appointment, make clear that 140 is now the golden child with the potential to make CYCC a BO target, similar to what happened with ARQL (which I owned from the 3's before we were bought by Merk for 20).
s
Acorn and Aspire are involved with 55% +holdings. Something fundamental is happening here. With a MC of 40M. This can go up to a level unseen before, with 3 updates coming any time from now.
Just a quick heads upl might be worth a small fortune. OTC: RDGL (Trading at 0.13) submitted a drug for breakthrough designation to the FDA and will get a response on or before Jan 16.
K
I find it interesting that the two most recent additions, Mark Kirschbaum hired as CMO back in October this year and Brian Schwartz added to the BOD this past week, were both formerly at Arqule when Merck purchased the company to acquire the BTKi that they both helped advance while at Arqule. Sure looks like they've brought some experienced people on board to advance their small molecule drugs (particularly CYC140) to a stage where CYCC becomes an attractive BO target.
M
Congrats recent buyers. Excellent gains today so far. Good luck going forward.
R
I'm trying to figure out why there are no comments on this board for a stock that seems really bullish lately...
Bullish
R
TEST
G
Take a look at GAXY it had a weekend pull back but the news for this stock and the covid stimulus bill with 82billion ear marked for schools for civid safty protocols they have a good business model and have moved up to average of 30 % each day for the last few days it should move up Monday and it is still at a good price 0.0280
C
Total cash > MC? And attractive pipeline?! Something is not right here about the price. The low float can mean explosive upside with news. Experts please chime in.
n
$8 by end of today and $12 tomorrow ISA
Bullish
G
"Spiro the Zero", must be back from Christmas vacation.
D
There is another on where most Big Pharma teamed up.....ONCY
https://finance.yahoo.com/news/cyclacel-pharmaceuticals-announces-market-7-130000954.html
response on or before Jan 16.
really bullish lately...
https://usanewsgroup.com/2020/02/24/why-biotechnology-companies-are-so-important/